Domain Continues to Invest in Rare Disease
July 7, 2015Domain Associates has a history of supporting the development therapeutics for rare disease. Most recently, portfolio company Celtaxsys, Inc., a clinical-stage development company focused on novel therapeutics to treat rare inflammatory diseases, completed a $40 million Series D financing and announced that Domain partner Nicole Vitullo will join Celtaxsys' board of directors.
More »
Fox News: New Impact Saves Vision
May 13, 2015Fox News recently featured a story about a patient with diabetic macular edema, a diabetes-related condition in which blood vessels in the eye leak, leading to vision loss. A few days after receiving Alimera's Iluvien implant, the patient got his vision back.
More »
CBS News Philly: Purple Day to Raise Epilepsy Awareness
March 26, 2015CBS News Philly 3 featured a story about Kayla Taylor, a four-year-old girl with PCDH19 female pediatric epilepsy. Domain's portfolio company Marinus Pharmaceuticals, is developing a potential treatment for the disorder.
More »
New York Times: From the Gates Foundation, Direct Investment, Not Just Grants
March 17, 2015An article in the New York Times highlights how the Bill & Melinda Gates Foundation foundation begun taking a new approach to achieving its goals—direct equity investments in private companies—including Domain Associates' portfolio company, Sera Prognostics. Domain partner Kim Karmdar discusses how Sera and Domain came to the decision to partner with the Gates Foundation.
More »
Shire Acquires Meritage Pharma
March 3, 2015Shire Pharmaceuticals acquired Meritage Pharma, which was in late-stage clinical trials for an orphan drug to treat a rare disease of the esophagus, for $70 million, with another $175 million dependent on Meritage meeting milestones down the road.
More »